Brind.

ADARx announces pricing for upsized IPO of next-generation siRNA therapeutics

1 report, 1 independent Updated Sep 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

ADARx Pharmaceuticals announced the pricing of its upsized initial public offering of 26,250,000 shares of common stock at $17.00 per share. The gross proceeds from the offering are expected to be approximately $446.3 million. The underwriters have a 30-day option to purchase up to an additional 3,937,500 shares.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The offering is being made through lead book-running managers including J.P. Morgan, Morgan Stanley, TD Cowen, and UBS Investment Bank. Shares are scheduled to begin trading on The Nasdaq Global Select Market on September 25, 2026.

From manilatimes.net

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Morgan StanleySpeculative

    Morgan Stanley could see a direct revenue increase from successful IPO underwriting fees.

  • UBSSpeculative

    UBS Investment Bank could see a direct revenue increase from serving as a lead book-running manager for the IPO.

  • Broadridge Financial SolutionsSpeculative

    TD Cowen could see a direct revenue increase from successful IPO underwriting fees.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped